@CathyEngMD's KRASCENDO-1 card has every number fellows need, including the one that matters in clinic: 30% had treated brain mets. Pearl: this was head to head against approved G1

MeDucation· @MeDucationai · X·2026-10-26 01:31· 3 天前评分70

正文 · 原文

@CathyEngMD's KRASCENDO-1 card has every number fellows need, including the one that matters in clinic: 30% had treated brain mets. Pearl: this was head to head against approved G12C inhibitors, not chemo, a high bar to clear. #ESMO26 #LCSM

6 浏览 · 0 赞 · 0 转发 · 0 回复

引用@

Impressive results: KRASCENDO-1 Phase III Divarasib vs. Sotorasib vs. Adagrasib (N= 338) for KRAS #G12C MT #NSCLC #lungcancer 🫁 - 30% had a history of treated brain met - majority had received Sotorasib 🔹Primary PFS: 9.8 vs. 5.7M; HR = 0.58 🔹Secondary OS: 17.7M vs. 12M (HR = 0.56) 🔹ORR: 58% vs. 32% #cancerresearch @OncoAlert #cancer @Roche #ESMO2026

在 X 查看被引用的帖子

来源：MeDucation · x.com